<DOC>
	<DOCNO>NCT00196742</DOCNO>
	<brief_summary>The Fabry Registry ongoing , international multi-center , strictly observational program track routine clinical outcome patient Fabry disease , irrespective treatment status . No experimental intervention involve ; patient Registry undergo clinical assessment receive care determine patient 's treating physician . The objective Registry : - To enhance understanding variability , progression , natural history Fabry disease , include heterozygous female disease ; - To assist Fabry medical community development recommendation monitor patient report patient outcome help optimize patient care ; - To characterize describe Fabry population whole ; - To evaluate long-term safety effectiveness Fabrazyme®</brief_summary>
	<brief_title>Fabry Disease Registry</brief_title>
	<detailed_description>The Fabry Registry international program ; addition central contact information provide `` Location '' heading , patient may contact : - In Asia-Pacific - Vivian Liu , +65-6431-2548 , Vivian.liu @ genzyme.com - In Europe - +31-35-699-1232 , europe @ FabryRegistry.com - In Latin America - +617-591-5500 , help @ FabryRegistry.com - In North America - +617-591-5500 , help @ FabryRegistry.com</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Inclusion Criteria All patient confirm diagnosis Fabry disease sign informed consent patient authorization form ( ) eligible inclusion . Confirmed diagnosis define documented deficiency plasma leukocyte αGAL ( alphagalactosidase ) enzyme activity and/or mutation ( ) gene cod αGAL . Exclusion Criteria There exclusion criterion Registry . Patients allow participate clinical study may receive different therapy treat disease ; however , enrollment clinical study note Registry case report form ( CRFs ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>alpha Galactosidase A</keyword>
	<keyword>aGAL ( alpha-galactosidase )</keyword>
	<keyword>Fabry</keyword>
	<keyword>GL3 ( globotriaosylceramide )</keyword>
	<keyword>Anderson-Fabry Disease</keyword>
	<keyword>angiokeratomas</keyword>
	<keyword>GLA deficiency ( gene deficiency )</keyword>
	<keyword>error metabolism</keyword>
</DOC>